Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-18
2008-10-07
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S122000
Reexamination Certificate
active
07432279
ABSTRACT:
The present invention provides compounds of formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5r6, m and n are defined as described herein. The invention also provides methods of making the compounds of formula (I), and methods of treating inflammatory diseases, such as rheumatoid arthritis, in a mammal comprising administering a therapeutically effective amount of a compound of formula (I) to the mammal.
REFERENCES:
patent: 6355636 (2002-03-01), Wissner et al.
patent: 6521618 (2003-02-01), Boschelli et al.
patent: 6548496 (2003-04-01), Wissner et al.
patent: 6689772 (2004-02-01), Boschelli et al.
patent: WO 00/66583 (2000-11-01), None
Wissner et al., Bioorganic & Medicinal Chemistry Letters, “Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles”, vol. 14, pp. 1411-1416.
Beinke et al., Molecular and Cellular Biology, “NF-kB1 p105 Negatively regulates TPL-2 MEK Kinase Activity”,2003, vol. 23, pp. 4739-4752.
Tsatsanis et al., Oncogene, “Tpl-2 induces IL-2 expression in T-cell lines by triggering multiple signaling pathways that activate NFAT and NF-kB”, vol. 17, 1998, pp. 2609-2618.
Gavrin et al., “Inhibition of Tpl2 kinase and TNF-α production with 1,7-naphtyridine-3-carbonitriles: Synthesis and structure-activity relationships,” Bioorganic & Medicinal Chemistry Letters, 15, 5288-92 (2005).
Green et al., “Inhibitors of Tumor Progression Loci-2 (Tpl2) Kinase and Tumor Necrosis Factor α (TNF-α) Production: Selectivity and in Vivo Antiinflammatory Activity of Novel 8-Substituted-4-anilino-6-aminoquinoline-3-carbonitriles,”J. Med. Chem.2007, 50, 4728-4745.
Hall et al., “Pharmacologic Inhibition of Tpl2 Blocks Inflammatory Responses in Primary Human Monocytes, Synoviocytes, and Blood,”J. Biol. Chem.2007, 282, 33295-33304.
Cuozzo John William
Gavrin Lori Krim
Gopalsamy Ariamala
Green Neal Jeffrey
Hu Yonghan
Fish & Richardson P.C.
Rahmani Niloofar
Seaman D. Margaret
Wyeth
LandOfFree
4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4003073